Abstract
Alzheimer’s disease (AD) is a multifactorial neurodegenerative disease, the primary cause of dementia in people over 65 years old. AD is characterized by two molecular hallmarks, the intracellular neurofibrillary tangles of tau and amyloid beta oligomers, which are aggregates of hyperphosphorylated tau and amyloid beta peptides, respectively. These hallmarks gave rise to the two main theories that have opened the way for available treatments, such as FDA-approved memantine, and Aβ (aducanumab, lecanemab) and tau immunotherapies. Tau immunotherapy, especially multitarget approaches, has been recently proven effective. However, drugs against amyloid plaques had a non-successful outcome, despite their contributions to AD knowledge. An innovative approach comes from the multitarget concept, based on bioactive molecules and nutraceuticals. Interestingly, the use of early detection biomarkers such as Alz-Tau®, SIMOA®, and the recent Lumipulse™ test, are an important support to orient AD therapies based on the modifications of the styles of life. This includes physical exercise, a healthy diet, mindfulness, and cognitive stimulation, among others. All of the above analyses are critical to switch the focus to the prevention of AD.
Graphical Abstract
Introduction
Alzheimer’s disease is currently the leading cause of dementia worldwide in elderly adults older than 65 years old (). Indeed, dementia is currently the third leading cause of death in the United States. Due to the accelerating aging in the population, its understanding and management represent a significant challenge in contemporary medicine, particularly given its status as the most prevalent cause of dementia in individuals over the age of 65 (Weninger et al., 2016; ). In a WHO report, in 2022, 50 million people were affected by dementia worldwide, and it’s projected that by 2050, 150 million people will be affected (). AD also constitutes a major puzzle for the world community, considering the enormous social and economic impacts on families and caregivers, as well as on the economies of the countries. This complex, multifactorial neurodegenerative disorder elicits a gradual decline in both cognitive and non-cognitive functions, generating a substantial burden on patients, their families, and broader society (). The molecular markers of Alzheimer’s disease pathology are classically defined by the presence of extracellular amyloid plaques, primarily composed of aggregated amyloid-beta peptides, and intracellular neurofibrillary tangles, which consist of hyperphosphorylated tau protein (; ; ). The initial identification of these neuropathological hallmarks by Alois Alzheimer in 1906 has led to the formulation of prominent yet contested theories regarding the disease’s etiology (Trejo-Lopez et al., 2022). The Amyloid Cascade Hypothesis postulates that the accumulation and aggregation of amyloid-beta peptides are the primary drivers of the disease, initiating a cascade of events that ultimately lead to neuronal dysfunction and death (Sadigh-Eteghad et al., 2015). Conversely, the Tau Hypothesis establishes that abnormalities in tau protein, such as hyperphosphorylation and subsequent aggregation into neurofibrillary tangles, are the central pathogenic events in Alzheimer’s disease (Maccioni et al., 2009, 2010; ). Despite the extensive research efforts directed toward these two prominent hypotheses, therapeutic strategies targeting either amyloid-beta or tau have yielded limited success, underscoring the complex and multifactorial nature of Alzheimer’s disease ().
Currently, only palliative treatments and post-clinical FDA-approved biomarkers are available in the clinic. Why have all the previous treatments failed to improve the quality of life of the patient and, consequently, of their caregivers? To answer that question, it is required to go to the multifactorial etiology of AD (). This disease goes beyond its major molecular hallmarks, the neurofibrillary tangles and the amyloid plaques. Several damage signals trigger the activation of the microglia, promoting neuroinflammation (Singh, 2022; Wang C. et al., 2023). This promotes a chronic pro-inflammatory microenvironment, which leads to neurodegeneration (). Current FDA-approved therapies, such as memantine (Parsons et al., 2013) and others, only act on one target, which would explain in part why the improvement of cognitive performance is not satisfactory. Now, novel therapies focus on multitarget strategies, usually combining nutraceuticals, bioactive compounds, such as Andean shilajit (), and a healthy diet. This has proven to be the best approach so far.
The etiopathogenesis of AD: Aβ, tau, or both?
In 1901, Alois Alzheimer described for the first time a case of a 50 years-old woman, Auguste Deter, the first reported case of Alzheimer’s disease. In the report, he described that Auguste had several memory issues, disorientation, and hallucinations, among other psychiatric symptoms. After passing in 1906, Dr. Alzheimer performed histological studies on her postmortem brain (Stelzmann et al., 1995). This allowed him to discover two abnormalities present in Auguste’s brain: amyloid plaques between the neurons and neurofibrillary tangles inside the neurons. This discovery established the two main hallmarks of AD: extracellular amyloid plaques, constituted by Aβ peptide, and neurofibrillary tangles, constituted by hyperphosphorylated tau protein (Roda et al., 2022; ). The accumulation of both amyloid peptide 1–42 and hyperphosphorylated tau protein generates oligomers (AβO and TauO, respectively), leading to a disruption of neuronal function and exerting a toxic influence on the brain, since they trigger the misfolding of adjacent proteins into aggregates or oligomers (Mroczko et al., 2019). However, the debate about which one is the principal contributor to the development and progression of AD has extended to the present day.
Current evidence states that regarding the amyloid plaques, which are constituted by AβO, these are also present in cognitively healthy elders (Rodrigue et al., 2012), in some cases even more than AD patients. Also, cognitive decline, the main symptom of AD, is not directly correlated with the amyloid-plaque burden in the brain, a reason why the current amyloid therapies had failed (). Despite those facts, new evidence has shed light on the involvement of some soluble Aβ fragments, among several other signals, which can be recognized by the microglia as a danger signal, and not the amyloid plaque as initially thought (Lučiūnaitė et al., 2020). The latter is supported by other evidence, demonstrating that through the gut-brain axis, some bacteria can secrete amyloid-like peptides and activate Alzheimer’s disease pathways in a neuronal cell line ().
Neurofibrillary tangles, on the other hand, are constituted by TauO. Tau is a microtubule-associated protein (MAP) whose main function is to direct the formation of microtubules that allow the formation of dendrites in neurons (). Hyperphosphorylation of tau protein leads to conformational structure changes, from an α-helix to a β-sheet, allowing their self-assembly into pair-helical filaments (PHF) and later, neurofibrillary tangles (Luna-Muñoz et al., 2007; ). It has been demonstrated that, contrary to amyloid plaques, hyperphosphorylated tau protein, and neurofibrillary tangles correlate well with cognitive decline and brain atrophy (Maccioni et al., 2006; Slachevsky et al., 2016). This process is illustrated on Figure 1. Thus, tau protein has now emerged as a novel candidate to conduct further research regarding novel therapies for AD and the development of early detection biomarkers, two milestones required to promote AD prevention and the slowing of the onset of cognitive symptoms.
FIGURE 1
Integration of several onset factors and new theories: neuroinflammation as the key feature
To understand AD, it is key to identify it as a multifactorial neurodegenerative disease. Several signals can trigger the onset and are also involved in the progression of the disease.
Two of the principal signals were discussed above, as the two main hallmarks in AD: amyloid plaques and neurofibrillary tangles. However, several other contributors either to the onset or the progression of AD can be mentioned:(i) Metabolic Dysfunction: This is perhaps one of the major contributors to metabolic issues, such as AD, alongside the main hallmarks. Evidence supports that AD brains have several lower expression of glucose transporters (; Liu et al., 2008) and brain insulin resistance (; ), just to mention a few. Also, it should be considered that patients with type 2 diabetes have 2.5 times higher risk of developing AD, and also AD patients have two times higher risk of developing type 2 diabetes (Sebastião et al., 2014; Mushtaq et al., 2015). In that regard, AD is now considered a novel type 3 diabetes (); (ii) Gut-brain axis and commensal bacteria: several studies sustain that AD patients suffer changes in the intestinal microbiota, promoting pro-inflammatory signals that reach the brain and trigger pro-inflammatory signals (; Varesi et al., 2022). Some of these bacteria can secrete amyloid-like peptides that can activate the microglia, in agreement with one of the original hypotheses. Studies on germ-free 3xTg mice model showed a significant reduction in amyloid plaques and neurofibrillary tangles as compared to the 3xTg control (). Also, the proinflammatory pathway C/EBPβ/AEP, associated with polyunsaturated fatty acids (PUFA), is downregulated in these germ-free 3xTg mice as compared to the 3xTg control (). Thus, gut microbiome regulates AD and associated cognitive disorders via PUFA-mediated neuroinflammation; (iii) Mitochondrial dysfunction: Emerging as a novel theory, mitochondrial dysfunction is now considered one of the relevant features in AD. In the brain, neurons require a high amount of energy to maintain synaptic function and plasticity (Reiss et al., 2024), and mitochondrial dysfunction is among the first detectable changes in AD. Mitochondrial dysfunction in AD compromises neuronal function and viability, contributing to the onset of AD symptoms due to early neuronal death (Reiss et al., 2024). This is closely related to other factors, such as metabolic dysregulation, calcium homeostasis disruption, oxidative stress and mitochondrial quality control impairment, all observed in AD (); (iv) Infections: it has been reported that viruses and bacteria that can cross the blood-brain barrier are related to cognitive decline and neuronal death, such as Herpes viruses (). Notably, a recent study demonstrated that vaccination against the herpes-zoster virus decreased dementia in elderly adults (); (v) Vascular dysfunction: As brain function depends on continuous delivery of oxygen and energy substrates, such as glucose, a suitable cerebral vasculature that allows these elements is required (). The regional cerebral blood flow (rCBF) is tightly regulated for this purpose. As part of the cerebral vasculature, the blood-brain barrier (BBB) regulates the passage of oxygen and nutrients and the removal of metabolic waste products. It also prevents entry of plasma constituents and protects the brain from infection (Zhao et al., 2015). In AD, vascular lesions such as arteriolosclerosis, microinfarcts, hemorrhage, atherosclerosis, and cerebral amyloid angiopathy are prevalent in 80% of cases diagnosed with AD (Toledo et al., 2013), all the later associated with a decrease in brain microcirculation (). These lesions lead to a reduction in the rCBF. This hypoperfusion is attributed to an impaired vascular regulation by soluble A (). This peptide is vasoactive and constricts arterioles. Also, it has been demonstrated that Aβ oligomers constrict capillaries (Nortley et al., 2019). This allowed to propose that vascular dysfunction could lead to AD ().
All of the above-mentioned onset signals have a common feature: the trigger of pro-inflammatory signals that activate microglia and promote a pro-inflammatory microenvironment in the brain (Rubio-Perez and Morillas-Ruiz, 2012; Twarowski and Herbet, 2023).
The latter is summarized in the neuroimmunomodulation theory (Maccioni et al., 2009, 2010), which states that it is a cyclic event, where these pro-inflammatory signals (especially tau-related signals) (Morales et al., 2013) activate the microglia and pro-inflammatory cytokines, such as IL-6 and TNF-α (Zheng et al., 2016; ), activate downstream signaling pathways, such as the one mediated by NFkβ and promote upregulation of key proteins, such as the kinases CDk5 and GSK3β (Zheng et al., 2005; ; Saito et al., 2019). This upregulation, in turn, leads to hyperphosphorylation of tau protein, which leads to the conformational changes that promote self-assembly, leading to the formation of paired-helical filaments and neurofibrillary tangles that eventually lead to neurodegeneration (). Fragments of these neurofibrillary tangles can act as signals for the activation of another microglia; thus, the cycle continues.
As we come to terms with the multifactorial nature of AD, summarized in Figure 2, it is no wonder that current therapeutic approaches have already failed.
FIGURE 2
Stress and the onset of Alzheimer’s disease
Human beings are viewed holistically as biopsychosocial individuals, with determining factors in their lives such as biological, genetic, chronological, and environmental factors. Environmental factors include stressors, which are one of the many causes of neurodegenerative diseases, including AD (; Stuart and Padgett, 2020).
Stress affects people of all genders and ages and varies according to each individual’s stressful experiences. When a person constantly faces stressors, physical and chemical changes occur that affect their health. Stress allows people to cope with the obstacles they encounter, and therefore, each individual will respond differently, assessing their ability to cope. Stress can be chronic, depending on the duration and intensity of the aversive event. Changes occur in the nervous system (CNS), which produce alterations in the entire organism, that will be expressed later as multiple disorders. When there are sudden changes in the nervous system, in order to maintain homeostasis, it is forced to demand compensation from the various systems, resulting in the overload of activity without control, and finally with consequences that primarily affect the proper functioning of the brain (Vallejo-Johnson and Marcial-Velastegui, 2018).
We understand that stress is a natural human response to situations of extreme emotional tension. It manifests itself in a state of intolerance and irritability in response to the life situation experienced. Cannon points out that the body reacts to threats by activating two systems: the sympathetic nervous system and the endocrine system (). When activated, the body returns to calm.
However, prolonged stress causes excess production of adrenaline, noradrenaline, glucocorticoids, and cortisol, which disrupt the body’s homeostasis process. This affects the neurons of the hippocampus, generating progressive neuronal loss that impairs activities of daily living, as reflected in AD. Lifestyles focused on physical exercise, cognitive stimulation, and a healthy diet can promote a more favorable adaptive response for emotional wellbeing and the homeostasis process the body faces in times of stress.
It is important to recognize stress as a major factor in AD pathogenesis, as it correlates with the onset of depressive symptoms or stress-related pathologies. It is worth noting that these stress-related pathologies could promote AD-type neurodegenerative disorders ().
Brain structures such as the hippocampus, amygdala, striatum, and cortex are actively involved in processing information associated with learning and memory. These cognitive processes induce changes in synaptic plasticity under normal conditions, but in patients or in transgenic animal models, these processes are affected by the development of AD type cognitive decline. In transgenic models of AD, the way this pathology affects synaptic plasticity has been studied. This work has been conducted at three levels of analysis: molecular, cellular, and cognitive-behavioral. There are behavioral tasks that induce a high release of stress hormones, which can affect learning and memory consolidation. AD can impair motor performance because certain tasks require good motor performance, reflecting cognitive impairment ().
AD biomarkers: in need of an early detection
The shortcomings of current monotarget therapeutic approaches highlight the critical need for early detection biomarkers that can identify individuals at risk of developing Alzheimer’s disease, potentially enabling preventative strategies or interventions that can delay or even halt the onset of clinical symptoms. However, current alternatives only include detection when the clinical symptoms are evident. Some of the current detection biomarkers for AD are:
- (i)
Neuroimages: This includes nuclear magnetic resonance (NMR) and positron-emission tomography (PET-scan) as the most relevant ones. These techniques involve computerized images. NMR imaging uses radio waves and strong magnetic fields to create detailed images of organs and tissues inside the body, in this case, the brain. Usually, brain atrophy is observed with this technique. PET-SCAN, on the other hand, uses fluorescent or radioactive tracers to visualize and measure metabolic processes and other physiological activities in the body, such as fluoro-deoxy-glucose. The FDA has approved PET-scan imaging with an amyloid-beta and tau probes (; ; Maschio and Ni, 2022; Wang R. et al., 2023), the most recent ones directed to tau as biomarkers for AD (Xia et al., 2013; Kolb and Andrés, 2017). Nevertheless, the main disadvantage is that this technology is expensive and only provides diagnosis once the cognitive decline is evident.
- (ii)
Cerebrospinal fluid (CSF) biomarkers: The other FDA-approved biomarkers for AD are those evaluated in CSF (Maccioni et al., 2006). Several antibodies are employed to detect either amyloid-beta, tau, and, more recently, phospho-tau, in CSF samples (Mattsson et al., 2017; ; ; McGrowder et al., 2021). These biomarkers can be evaluated using several techniques, with the most commonly used being an ELISA (enzyme-linked immunosorbent assay), according to the National Institutes of Health (NIH). Nonetheless, CSF sampling is an invasive procedure that requires trained personnel. Also, since it provides a diagnosis after the manifestation of cognitive decline symptoms, it is not useful for early detection.
While neuroimaging techniques such as PET scans and cerebrospinal fluid analysis for biomarkers like tau, phosphorylated tau, and amyloid-beta peptide are employed for diagnosis, their limitations in providing early detection and their invasive nature require the development of more accessible and sensitive diagnostic tools. Thus, current FDA-approved biomarkers for AD do not allow early detection. Added to that, the costs (over US$1000 for PET-SCANS and US$650 for CSF tests) and accessibility to these tests are a severe limitation for a routine-based implementation in low-income countries, which exhibit the highest rate of increase in AD. Thus, at present, efforts are leading to the implementation of cost-effective biomarkers that provide early detection, which allows screening of patients before the manifestation of cognitive decline.
- (iii)
Blood-based biomarkers: Due to the lack of early detection biomarkers, efforts have been made to develop cost-effective early detection biomarkers, which must be accessible and less invasive for the patients (; ). In this regard, several blood-based biomarkers are evaluated, in which we can highlight (a) The Alz-tau biomarker: validated by four clinical trials, this novel blood-based biomarker allows screening of pre-clinical populations at risk of developing AD. It is based on the detection of platelet tau variants, including high-molecular-weight (HMW) and low-molecular-weight (LMW) forms (), using a novel tau-51 monoclonal antibody () in a western blot analysis. The HMW/LMW ratio correlates with brain atrophy and cognitive decline and allows screening of presymptomatic subjects. Currently, it is implemented in several hospitals and clinical laboratories; (b) Ultrasensitive SIMOA® assay detection: another high-end novel biomarker is based on a novel SIMOA® assay, which allows ultrasensitive detection of tau protein in serum and also CSF, at levels of pg/ml (; ). This novel technology is used for detecting and quantifying specific biomolecules, primarily proteins, in various biological samples. It is based on the isolation of individual immunocomplexes within femtoliter-sized reaction chambers, enabling the detection and counting of single molecules. This approach allows SIMOA® to detect biomarkers at concentrations up to 1,000 times lower than traditional ELISA methods, often reaching the femtomolar (fg/mL) range. Currently, two of these SIMOA® platforms, which detect ptau181 and ptau217, were recognized by the FDA as a breakthrough device due to the test’s potential for more effective diagnosis of AD; (c) Lumipulse technology: This technique uses chemiluminescent enzyme immunoassay (CLEIA) to measure biomarkers in bodily fluids, like blood or cerebrospinal fluid, for various diagnostic purposes. This technology has been evaluated in Alzheimer’s disease (; ; ). Recently, one of these platforms, Lumipulse G pTau217/ß-Amyloid 1-42, which evaluates the plasma ratio between ptau217 and amyloid 1-42, received a breakthrough device recognition by the FDA.
Additionally, other biomarkers are being tested, such as those using mass spectrometry (). One of them, PrecivityAD2, which generates a ptau-217 and aβ 42/40 ratio, was clinically validated (Meyer et al., 2024). However, all of them require to be validated by neuropsychological tests to confirm the diagnosis.
This reflects the current advances in the search of early detection biomarkers, which is ongoing. Some of the former mentioned tests are being clinically implemented but not as a routine-based test, while others are still on clinical validation trials.
Therapeutic approaches for AD: monotarget, multitarget and novel approaches
Current therapeutic interventions approved by regulatory agencies such as the FDA offer only symptomatic relief or aim to slow the progression of cognitive decline, without addressing the underlying disease mechanism (Wang Y. et al., 2023). The multifactorial nature of AD can explain, at least in part, why several therapeutic approaches failed. In this regard, current therapies for AD can be subdivided into two:
- (a)
Monotarget therapies: These therapies aim at a single pharmacological target. The FDA-approved drugs are classified as monotarget, such as memantine, a cholinesterase inhibitor (Parsons et al., 2013; Tang et al., 2023). Novel current therapies include monoclonal antibodies that act against amyloid-beta have also been approved by the FDA: aducanumab, lecanemab, and donanemab (; PR Newswire, 2023; Söderberg et al., 2023). Currently, aducanumab is on phase IV clinical trial, and lecanemab in 2023 was approved by the FDA. However, as discussed above, amyloid beta does not have a direct relation with cognitive impairment in AD, not the way tau protein does. Which is why the majority (if not all) of the therapeutic approaches based on amyloid-beta have failed, due to lack of efficiency and some severe side-effects (; ; Kurkinen, 2023). That is why novel therapies that target tau protein. In a recent study, a novel tau monoclonal antibody, specific for insoluble tau, employed as a therapeutic approach, improved tau pathology through the cytosolic antibody receptor TRIM21(Mukadam et al., 2023). The limitations of mono-target therapeutic approaches in Alzheimer’s disease have prompted a shift toward multi-targeting strategies that address multiple pathological pathways simultaneously (Maccioni et al., 2020).
- (b)
Multitarget therapies: These multi-targeted approaches may involve the combination of components targeting different aspects of the disease, such as amyloid-beta production, tau phosphorylation, neuroinflammation, and oxidative stress. In this group, we can find all bioactive compounds, nutraceuticals, and functional foods that aim at more than one target. Some examples are nutraceutical formulations such as Brain-Up10® or Durabrain™ in United States, multicomponent with several bioactive molecules containing Andean shilajit and vitamin B complex (; ; ), which is supported by clinical trials. Then, we have bioactive compounds such as curcumin (Tang et al., 2017; Voulgaropoulou et al., 2019) and quercetin (Zaplatic et al., 2019; ), and functional foods such as berries (Subash et al., 2014), which are rich in anthocyanins (Sohanaki et al., 2016; Ma et al., 2018) and polyphenols (Reddy et al., 2020; ; Li et al., 2023). This approach has been proven to be the most effective therapy to delay the progression and improve cognitive performance in AD.
It is worth mentioning that in the context of AD therapy, other novel approaches are:
- (c)
Immunotherapy: This could be summarized in (i)Active immunotherapy: anti-Aβ vaccines, such as AN1792, the first one to be tested clinically (Thatte, 2001). However, during phase IIA, 6% of the patients developed meningoencephalitis due to an excessive Th-1-mediated inflammation. Currently, UB311 is on phase II clinical trial. This vaccine is composed by two synthetic T-helper peptide epitopes linked to Aβ 1-14 and possess safety vaccine designs and a delivery mechanism that increases Th-2 response (Wang et al., 2017). AADVac1, on the other hand is a tau epitope-based vaccine which induces specific antibodies targeting 3 or 4 conformational epitopes (Novak et al., 2019). AADVac1 treatment resulted in less brain atrophy and reduced cognitive impairment in a Phase I clinical trial. (ii) Passive immunotherapy: This therapy involves passive administration of monoclonal antibodies generated against the target protein, in this case, Aβ 1-42. Some of the monoclonal antibodies employed for Aβ- based immunotherapy are lecanemab and aducanumab, which are currently going on a phase II/III clinical trials (Thatte, 2001). Even though aducanumab was approved in 2021 by the FDA, a new phase II clinical trial is required to evaluate safety and efficiency as vasogenic edema was developed in trials ().
Anti-tau-based immunotherapy includes Zagotenemab, Tilavonemab, and bepranemab among others (Thatte, 2001). Semorinemab can bind to the six human tau isoforms and protect neurons, and a study in patients with moderate AD was performed (). Phase 2 clinical trial of Zagotenemab showed increase in ptau181 and adverse effects with no efficiency (). Tilavonemab was discontinued due to the lack of efficiency (West et al., 2017).
All the efficiencies and safety were compared in a recent study by ). This study showed that Semorinemab was more effective in terms of cognitive decline prevention.
- (d)
Stem cell therapy: A novel potential therapy worth to be explored is the stem cell therapy for AD. Four types of stem cells are available: embryonic stem cells, induced pluripotent stem cells, neural stem cells (NSCs) and mesenchymal stem cells (). Using AD rodent models, it was demonstrated that NSCs reduce tau and Aβ expression levels (Lee et al., 2015); promote neurogenesis and synapse formation (; Lilja et al., 2015), reduce neuroinflammation (Zhang et al., 2016); and reverse cognitive deficits (; Lilja et al., 2015; Zhang et al., 2016). Several clinical trials of stem cell therapy are ongoing (), in Phase I and II. And more recently, a phase II study with laromestrocel demonstrated its efficiency and safety, as at 39 weeks post-treatment, it significantly reduced hippocampal atrophy, which correlated with an improvement in cognitive performance evaluated by MMSE (Rash et al., 2025).
AD prevention: the five major tips to prevent and slow-down its progression
All the former therapeutic approaches and early detection are key for AD prevention or to slow down its progression. It is known that sporadic AD can be decreased if we modify our lifestyle (; ), aligning at least with these major factors:
- (i)
Exercise: Sedentary life is a risk factor for the development of AD; thus, exercise is a key player in AD prevention, especially aerobic exercise (Morris et al., 2017; Meng et al., 2020; López-Ortiz et al., 2021). It has been demonstrated that exercise stimulates the secretion of a neuroprotective hormone, irisin (), which promotes the downregulation of the ERK-STAT3 pathway through the release of neprylisin (). It was demonstrated that irisin rescues synaptic plasticity alongside the FNDC5 protein, which is associated with neuroplasticity, in an exercise-linked manner on Alzheimer’s disease mouse models (Lourenco et al., 2019). This is consistent with other studies that presented correction in memory deficits in mouse models of AD (Lourenco et al., 2017) and protective pathways in rat hippocampus (Lourenco et al., 2022). On the other hand, exercise also promotes the increase of brain-derived neurotrophic factor (BDNF) in people with multiple sclerosis (Shobeiri et al., 2022). This is also consistent with the stimulation of adult hippocampal neurogenesis (AHN) and the increase of BDNF in 5xFAD mice (). Thus, within neurodegenerative diseases, such as AD and multiple sclerosis, exercise has neuroprotective effects (Mahalakshmi et al., 2020).
- (ii)
Healthy diet: a diet rich in antioxidants, such as the Mediterranean diet, rich in vegetables, fruits, whole grains, olive oil, beans, and fish, is pivotal to prevent AD (Solch et al., 2022). Also, it helps to keep balance in the gut microbiota (Solch et al., 2022; ), since a gut dysbiosis generates damage signals, such as LPS and amyloid-like peptides, that promote neuroinflammation (Leblhuber et al., 2021), generally associated with a proinflammatory diet (Shi et al., 2023). Consistent with the latter, the Mediterranean diet improved main cognitive functions in AD patients (). Another example is the ketogenic diet, which is high-fat, moderate-protein, very-low-carbohydrate eating plan that induces a state of ketosis in the body (Lange et al., 2017). This opens new avenues in the treatment of Alzheimer’s disease, since this diet can effectively reduce the accumulation of amyloid-beta and tau proteins (Oliveira et al., 2024), reduce neuroinflammation (Xu et al., 2022), stimulate synaptic plasticity () and modulate the gut microbiome () among other effects.
- (iii)
Meditation/mindfulness: Meditation may offer promising benefits for individuals with Alzheimer’s disease (AD) and mild cognitive impairment (MCI), potentially slowing cognitive decline and improving well-being, as well as promoting AD prevention (; ; ). Meditation improves cognitive function in adults with cognitive decline (). Also, it improves the blood flow to the brain (), and promotes structural changes in patients with MCI or AD (), which includes a reduction of brain atrophy. This in turn improves brain connectivity. Also, meditation downregulates stress and anxiety, some of the most common neuropsychological symptoms in AD ().
- (iv)
Cognitive stimulation: solving puzzles, reading, and writing by hand promote cognitive stimulation, which in preclinical AD is associated with brain structure and cognitive function (Schultz et al., 2015). Studies have shown that in AD patients undergoing cognitive stimulation programs improve their cognitive plasticity (Zamarrón Cassinello et al., 2008) and in early-stage AD, it improves neuropsychological symptoms such as apathy (). Also, cognitive stimulation improves connectivity and cognition in AD patients (). Indeed, multisensory stimulation had a positive effect not only on cognition but also decreased depression and anxiety levels, thus improving neuropsychological symptoms on AD patients (Ozdemir and Akdemir, 2009).
- (v)
Nutraceuticals and supplements: In addition to a healthy diet, it is important to complement it with relevant nutraceuticals and supplements that could benefit cognitive health and preserve brain function. A nutraceutical formulation, Brain-Up 10®, containing Andean shilajit and Vitamin B complex (), has been validated in clinical trials (). The Andean shilajit is rich in humic and fulvic acids, compounds that promote disassembly of tau fibrils in vitro (). This formulation improves neuropsychological symptoms in patients, especially apathy (). In a pre-clinical study, the shilajit and Brain-Up 10® formulation increased the number of neuronal processes and their length (). When the Andean shilajit was chemically fractionated, a neuritogenic effect in vitro of the fractions was observed, which was higher than that of the shilajit (). Regarding functional compounds, we can mention several, such as polyphenols (; ), flavonoids (), anthocyanins (Ma et al., 2018; ), quercetin (Zaplatic et al., 2019; Zhang et al., 2020; ) and curcumin (Tang et al., 2017; Voulgaropoulou et al., 2019; Shao et al., 2023; ), just to mention a few. These bioactive compounds are characterized by their anti-inflammatory, antioxidant effect, alongside other particular properties such as epigenetic regulation of key molecular pathways involved in AD. Finally, regarding supplements, vitamins B9 and B12 promote neuroprotection, improving synaptic plasticity (Mehrdad et al., 2023) and reducing neuroinflammation (). It should be considered that high levels of homocysteine are considered a risk factor for AD (Miller, 1999; Seshadri et al., 2002). Vitamins B12 and B9 act as coenzymes for remethylation and posterior conversion to methionine (McCaddon and Miller, 2023), which would prevent hyperhomocysteinemia.
These major scopes for AD prevention/slow-down progression are summarized in Figure 3.
FIGURE 3
A recent United States POINTERS study demonstrated that with a structured lifestyle intervention, including MIND diet, regular moderate-to-high-intensity physical exercise, social engagement, cognitive challenge and cardiovascular health monitoring, a significant improvement in global cognition was observed (). The latter includes at least 4 of the 5 scopes previously mentioned. Therefore, it is very relevant an early detection by sensitive biomarkers (), since it will allow an opportune intervention using clinically guided lifestyle changes.
Conclusion
In this review, we briefly summarize the state-of-the-art regarding new frontiers in Alzheimer’s disease, from its etiopathogenesis to the most recent research in terms of effective therapies, biomarkers, and preventive measures. Given that even modest advances in therapeutic and preventative strategies that lead to small delays in the onset and progression of Alzheimer’s disease can significantly reduce the global burden of this disease (), the development of effective interventions remains a high priority. The precise mechanisms underlying the pathogenesis of Alzheimer’s Disease are incompletely understood, but involve a complex interplay of genetic predisposition, environmental factors, and lifestyle influences.
However, for any treatment or preventive measure to be effective, it is necessary to screen patients in a pre-clinical stage, before the manifestation of the neuropsychological symptoms. Current FDA-approved biomarkers, such as PET scans and CSF biomarkers, only provide diagnosis in a post-clinical stage, when the neuropsychological symptoms are evident. Added to that, they are expensive and invasive, thus they are not a routine-based test that could be taken for preventive scopes. Now, current research is focused on providing a cost-effective, early-detection, blood-based biomarker. An example of this is the Alz-tau® biomarker (), which is clinically validated and implemented in several health facilities. The challenge of blood-based biomarkers is that the proteins employed as biomarkers are in low quantity in blood or serum, which is why novel technologies such as SIMOA® and Lumipulse® provide ultrasensitive detection. However, implementing these technologies on a routine basis in clinical examination is still ongoing.
Since advances in terms of effective therapies and early-detection biomarkers are noted, but insufficient, prevention is key (Weninger et al., 2016; ). Changes in lifestyle, such as adopting a Mediterranean diet, exercising, and reading to promote cognitive stimulation, may be key to preventing the cognitive decline associated with AD.
Further research is needed to identify and validate novel drug targets and to develop innovative therapeutic strategies that can effectively prevent, delay, or reverse the progression of this devastating disease.
Statements
Author contributions
AG: Conceptualization, Writing – review & editing, Investigation, Writing – original draft, Formal analysis. SG: Conceptualization, Writing – original draft, Investigation. RM: Visualization, Formal analysis, Resources, Validation, Project administration, Writing – review & editing, Conceptualization, Supervision, Writing – original draft, Investigation.
Funding
The author(s) declare that financial support was received for the research and/or publication of this article. This work was funded by the MACCIONI FOUNDATION and by a CORFO grant no. 24CVI-205060.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The authors declare that no Generative AI was used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1
Abdul-RahmanT.AwuahW.MikhailovaT.KalmanovichJ.MehtaA.NgJ.et al (2024). Antioxidant, anti-inflammatory and epigenetic potential of curcumin in Alzheimer’s disease.Biofactors50693–708. 10.1002/biof.2039
2
AbyadehM.GuptaV.PauloJ.MahmoudabadA.ShadfarS.MirshahvaladiS.et al (2024). Amyloid-beta and tau protein beyond Alzheimer’s disease.Neural Regen. Res.191262–1276. 10.4103/1673-5374.386406
3
AfzalM.RedhaA.AlHasanR. (2019). Anthocyanins potentially contribute to defense against Alzheimer’s disease.Molecules24:4255. 10.3390/molecules24234255
4
AfzalS.MaqsoodM.KhanU.MehmoodI.NawazH.AadilF.et al (2021). Alzheimer disease detection techniques and methods: A review.Int. J. Interact. Multimedia Artif. Intell.6:5. 10.9781/ijimai.2021.04.005
5
AgerR.DavisJ.AgazaryanA.BenaventeF.PoonW.LaFerlaF.et al (2015). Human neural stem cells improve cognition and promote synaptic growth in two complementary transgenic models of Alzheimer’s disease and neuronal loss.Hippocampus25813–826. 10.1002/hipo.22405
6
AhmadF.SachdevaP. (2022). A consolidated review on stem cell therapy for treatment and management of Alzheimer’s disease.Aging Med.5182–190. 10.1002/agm2.12216
7
AhmadF.KaranA.SharmaR.SharmaN.SundarV.JayarajR.et al (2024). Evolving therapeutic interventions for the management and treatment of Alzheimer’s disease.Ageing Res. Rev.95:102229. 10.1016/j.arr.2024.102229
8
Alzheimer Association (2024). Alzheimer’s disease facts and figures.Alzheimers Dement.203708–3821. 10.1002/alz.13809
9
AndradeV.Wong-GuerraM.CortésN.PastorG.GonzálezA.CalfíoC.et al (2023). Scaling the Andean Shilajit: A novel neuroprotective agent for Alzheimer’s disease.Pharmaceuticals16:960. 10.3390/ph16070960
10
ArndtJ.QianF.SmithB.QuanC.KilambiK.BushM.et al (2018). Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β.Sci. Rep.8:6412. 10.1038/s41598-018-24501-0
11
AshtonN. J.Puig-PijoanA.Milà-AlomàM.Fernández-LebreroA.García-EscobarG.González-OrtizF.et al (2023b). Plasma and CSF biomarkers in a memory clinic: Head-to-head comparison of phosphorylated tau immunoassays.Alzheimers Dement.191913–1924. 10.1002/alz.12841
12
AshtonN. J.BrumW. S.Di MolfettaG.BenedetA. L.ArslanB.JonatisE.et al (2023a). Diagnostic accuracy of the plasma ALZpath pTau217 immunoassay to identify Alzheimer’s disease pathology.medRxiv [Preprint]. 10.1101/2023.07.11.23292493
13
AtwoodC.PerryG. (2023). Playing Russian roulette with Alzheimer’s disease patients: Do the cognitive benefits of lecanemab outweigh the risk of edema, stroke and encephalitis?J. Alzheimers Dis.92799–801. 10.3233/JAD-230040
14
AyalonG.LeeS.AdolfssonO.Foo-AtkinsC.AtwalJ.BlendstrupM.et al (2021). Antibody semorinemab reduces tau pathology in a transgenic mouse model and engages tau in patients with Alzheimer’s disease.Sci. Transl. Med.13:eabb2639. 10.1126/scitranslmed.abb2639
15
BakerL.EspelandM.WhitmerR.SnyderH.LengX.LovatoL.et al (2025). Structured vs self-guided multidomain lifestyle interventions for global cognitive function: The US POINTER randomized clinical trial.JAMA2025:e2512923. 10.1001/jama.2025.12923
16
BarthélemyN.BatemanR.HirtzC.MarinP.BecherF.SatoC.et al (2020). Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer’s disease and PET amyloid-positive patient identification.Alzheimers Res. Ther.12:26. 10.1186/s13195-020-00596-4
17
BayoumyS.VerberkI.den DulkB.HussainaliZ.ZwanM.van der FlierW.et al (2021). Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231.Alzheimers Res. Ther.13:198. 10.1186/s13195-021-00939-9
18
BehfarQ.RichterN.KuralM.ClemensA.BehfarS.FolkertsA.et al (2023). Improved connectivity and cognition due to cognitive stimulation in Alzheimer’s disease.Front. Aging Neurosci.15:1140975. 10.3389/fnagi.2023.1140975
19
Bello-MedinaP.González-FrancoD.Vargas-RodríguezI.Díaz-CintraS. (2022). Oxidative stress, the immune response, synaptic plasticity, and cognition in transgenic models of Alzheimer disease.Neurologia37682–690. 10.1016/j.nrl.2019.06.002
20
Blanco-MíguezA.TamésH.Ruas-MadiedoP.SánchezB. (2021). Microbiota-derived β-amyloid-like peptides trigger Alzheimer’s disease-related pathways in the SH-SY5Y neural cell line.Nutrients13:3868. 10.3390/nu13113868
21
BlennowK.de LeonM.ZetterbergH. (2006). Alzheimer’s disease.Lancet368387–403. 10.1016/S0140-6736(06)69113-7
22
BoscoD.FavaA.PlastinoM.MontalciniT.PujiaA. (2011). Possible implications of insulin resistance and glucose metabolism in Alzheimer’s disease pathogenesis.J. Cell Mol. Med.151807–1821. 10.1111/j.1582-4934.2011.01318.x
23
BrickmanA.ManlyJ.HonigL.SanchezD.Reyes-DumeyerD.LantiguaR.et al (2021). Plasma p-tau181, p-tau217, and other blood-based Alzheimer’s disease biomarkers in a multi-ethnic, community study.Alzheimers Dement.171353–1364. 10.1002/alz.12301
24
BrionJ. (1998). Neurofibrillary tangles and Alzheimer’s disease.Eur. Neurol.40130–140. 10.1159/000007969
25
BrookmeyerR.JohnsonE.Ziegler-GrahamK.ArrighiH. (2007). Forecasting the global burden of Alzheimer’s disease.Alzheimers Dement.3186–191. 10.1016/j.jalz.2007.04.381
26
BuettnerL. L.FitzsimmonsS.AtavS.SinkK. (2011). Cognitive stimulation for apathy in probable early-stage Alzheimer’s.J. Aging Res.2011:480890. 10.4061/2011/480890
27
CaiW.ZhangH.WuY.YaoY.ZhangJ. (2025). Comparative the efficacy and safety of gosuranemab, semorinemab, tilavonemab, and zagotenemab in patients with Alzheimer’s disease: A systematic review and network meta-analysis of randomized controlled trials.Front. Aging Neurosci.16:1465871. 10.3389/fnagi.2024.1465871
28
CannonW. B. (1932). The wisdom of the body.New York, NY: W.W Norton & Co. Inc.
29
Carrasco-GallardoC.FaríasG.FuentesP.CrespoF.MaccioniR. (2012a). Can nutraceuticals prevent Alzheimer’s disease? Potential therapeutic role of a formulation containing shilajit and complex B vitamins.Arch. Med. Res.43699–704. 10.1016/j.arcmed.2012.10.010
30
Carrasco-GallardoC.GuzmánL.MaccioniR. (2012b). Shilajit: A natural phytocomplex with potential procognitive activity.Int. J. Alzheimers Dis.2012:674142. 10.1155/2012/674142
31
CarusoG.GodosJ.PriviteraA.LanzaG.CastellanoS.ChillemiA.et al (2022). Phenolic acids and prevention of cognitive decline: Polyphenols with a neuroprotective role in cognitive disorders and Alzheimer’s disease.Nutrients14:819. 10.3390/nu14040819
32
ChandraA.ValkimadiP.PaganoG.CousinsO.DervenoulasG.PolitisM.et al (2019). Applications of amyloid, tau, and neuroinflammation PET imaging to Alzheimer’s disease and mild cognitive impairment.Hum. Brain Mapp.405424–5442. 10.1002/hbm.24782
33
ChenC.LiaoJ.XiaY.LiuX.JonesR.HaranJ.et al (2022). Gut microbiota regulate Alzheimer’s disease pathologies and cognitive disorders via PUFA-associated neuroinflammation.Gut712233–2252. 10.1136/gutjnl-2021-326269
34
ChenH.LiuS.GeB.ZhouD.LiM.LiW.et al (2021). Effects of folic acid and vitamin B12 supplementation on cognitive impairment and inflammation in patients with Alzheimer’s disease: A randomized, single-blinded, placebo-controlled trial.J. Prev. Alzheimers Dis.8249–256. 10.14283/jpad.2021.22
35
ChenY.ZhangJ.ZhangT.CaoL.YouY.ZhangC.et al (2020). Meditation treatment of Alzheimer disease and mild cognitive impairment: A protocol for systematic review.Medicine99:e19313. 10.1097/MD.0000000000019313
36
ChiangM.TsaiT.WangC. (2023). The potential benefits of quercetin for brain health: A review of anti-inflammatory and neuroprotective mechanisms.Int. J. Mol. Sci.24:6328. 10.3390/ijms24076328
37
ChoiD.LeeY.HongJ.LeeH. (2012). Antioxidant properties of natural polyphenols and their therapeutic potentials for Alzheimer’s disease.Brain Res. Bull.87144–153. 10.1016/j.brainresbull.2011.11.014
38
ChoiS.BylykbashiE.ChatilaZ.LeeS.PulliB.ClemensonG.et al (2018). Combined adult neurogenesis and BDNF mimic exercise effects on cognition in an Alzheimer’s mouse model.Science361:eaan8821. 10.1126/science.aan8821
39
CilentoE.JinL.StewartT.ShiM.ShengL.ZhangJ. (2019). Mass spectrometry: A platform for biomarker discovery and validation for Alzheimer’s and Parkinson’s diseases.J. Neurochem.151397–416. 10.1111/jnc.14635
40
CornejoA.JiménezJ.CaballeroL.MeloF.MaccioniR. (2011). Fulvic acid inhibits aggregation and promotes disassembly of tau fibrils associated with Alzheimer’s disease.J. Alzheimers Dis.27143–153. 10.3233/JAD-2011-110623
41
Crespo-BielN.TheunisC.Van LeuvenF. (2012). Protein tau: Prime cause of synaptic and neuronal degeneration in Alzheimer’s disease.Int. J. Alzheimers Dis.2012:251426. 10.1155/2012/251426
42
CuljakM.PerkovicM.UzunS.StracD.ErjavecG.LekoM.et al (2020). The association between TNF-alpha, IL-1 alpha and IL-10 with Alzheimer’s Disease.Curr. Alzheimer Res.17972–984. 10.2174/1567205017666201130092427
43
de la Rubia OrtíJ. E.García-PardoM. P.DrehmerE.Sancho CantusD.Julián RochinaM.AguilarM. A.et al (2018). Improvement of main cognitive functions in patients with Alzheimer’s disease after treatment with coconut oil enriched mediterranean diet: A pilot study.J. Alzheimers Dis.65577–587. 10.3233/JAD-180184
44
de la TorreJ. C.MussivandT. (1993). Can disturbed brain microcirculation cause Alzheimer’s disease?Neurol. Res.15146–153. 10.1080/01616412.1993.11740127
45
DeatlyA.HaaseA.FewsterP.LewisE.BallM. (1990). Human herpes virus infections and Alzheimer’s disease.Neuropathol. Appl. Neurobiol.16213–223. 10.1111/j.1365-2990.1990.tb01158.x
46
Di LucenteJ.PersicoG.ZhouZ.JinL.RamseyJ.RutkowskyJ.et al (2024). Ketogenic diet and BHB rescue the fall of long-term potentiation in an Alzheimer’s mouse model and stimulates synaptic plasticity pathway enzymes.Commun. Biol.7:195. 10.1038/s42003-024-05860-z
47
DietrichH.XiangC.HanB.ZipfelG.HoltzmanD. (2010). Soluble amyloid-beta, effect on cerebral arteriolar regulation and vascular cells.Mol. Neurodegener.5:15. 10.1186/1750-1326-5-15
48
DilmoreA.MartinoC.NethB.WestK.ZemlinJ.RahmanG.et al (2023). Effects of a ketogenic and low-fat diet on the human metabolome, microbiome, and foodome in adults at risk for Alzheimer’s disease.Alzheimers Dement.194805–4816. 10.1002/alz.13007
49
DissanayakaD.JayasenaV.Rainey-SmithS.MartinsR.FernandoW. (2024). The role of diet and gut microbiota in Alzheimer’s disease.Nutrients16:412. 10.3390/nu16030412
50
DoyleC.DuntD.MorrisP. (2014). Stress and dementia.Int. Psychogeriatr.261235–1236. 10.1017/S1041610214001033
51
DwivediM.DubeyN.PansariA.BapiR.DasM.GuhaM.et al (2021). Effects of meditation on structural changes of the brain in patients with mild cognitive impairment or Alzheimer’s disease dementia.Front. Hum. Neurosci.15:728993. 10.3389/fnhum.2021.728993
52
EytingM.XieM.HeßS.GeldsetzerP. (2023). Causal evidence that herpes zoster vaccination prevents a proportion of dementia cases.medRxiv [Preprint]. 10.1101/2023.05.23.23290253
53
FleisherA.MunsieL.PerahiaD.AndersenS.HigginsI.HauckP.et al (2024). Assessment of efficacy and safety of zagotenemab: Results from PERISCOPE-ALZ, a phase 2 study in early symptomatic Alzheimer disease.Neurology102:e208061. 10.1212/WNL.0000000000208061
54
GarcíaM.AvilaM.BlancoC.Rodríguez-FernándezJ.Avendaño-UribeB.CasilimasD. (2012). El Estrés crónico, ¿factor de riesgo para la enfermedad de alzheimer?Rev. Ecuat. Neurol.2169–77.
55
GobomJ.ParnettiL.Rosa-NetoP.VyhnalekM.GauthierS.CataldiS.et al (2022). Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid.Clin. Chem. Lab. Med.60207–219. 10.1515/cclm-2021-0651
56
GonzálezA.SinghS.ChurrucaM.MaccioniR. (2022b). Alzheimer’s disease and tau self-assembly: In the search of the missing link.Int. J. Mol. Sci.23:4192. 10.3390/ijms23084192
57
GonzálezA.CalfíoC.ChurrucaM.MaccioniR. (2022a). Glucose metabolism and AD: Evidence for a potential diabetes type 3.Alzheimers Res. Ther.14:56. 10.1186/s13195-022-00996-8
58
GonzálezA.CalfioC.LüttgesV.González-MadridA.GuzmánC. (2023). The multifactorial etiopathogenesis of Alzheimer’s disease: Neuroinflammation as the major contributor.J. Alzheimers Dis.9495–100. 10.3233/JAD-230150
59
GonzálezA.Guzmán-MartínezL.MaccioniR. (2020). Plasma Tau variants detected by a novel anti-tau monoclonal antibody: A potential biomarker for Alzheimer’s disease.J. Alzheimers Dis.77877–883. 10.3233/JAD-200386
60
González-MadridA.CalfíoC.GonzálezA.LüttgesV.MaccioniR. (2023). Toward prevention and reduction of Alzheimer’s disease.J. Alzheimers Dis.96439–457. 10.3233/JAD-230454
61
Guzman-MartinezL.FaríasG.TapiaJ.SánchezM.FuentesP.GlogerS.et al (2021b). Interventional study to evaluate the clinical effects and safety of the nutraceutical compound BrainUp-10® in a cohort of patients with Alzheimer’s disease: A multicenter, randomized, double-blind, and placebo-controlled trial.J. Alzheimers Dis.811231–1241. 10.3233/JAD-201501
62
Guzman-MartinezL.CalfíoC.FariasG.VilchesC.PrietoR.MaccioniR. (2021a). New Frontiers in the prevention, diagnosis, and treatment of Alzheimer’s disease.J. Alzheimers Dis.82S51–S63. 10.3233/JAD-201059
63
Guzmán-MartínezL.TapiaJ.FaríasG.GonzálezA.EstrellaM.MaccioniR. (2019). The Alz-tau biomarker for Alzheimer’s disease: Study in a Caucasian population.J. Alzheimers Dis.671181–1186. 10.3233/JAD-180637
64
HaassC.SelkoeD. (2022). If amyloid drives Alzheimer disease, why have anti-amyloid therapies not yet slowed cognitive decline?PLoS Biol.20:e3001694. 10.1371/journal.pbio.3001694
65
HaddadH.MaloneG.ComardelleN.DegueureA.KayeA.KayeA. (2022). Aducanumab, a novel anti-amyloid monoclonal antibody, for the treatment of Alzheimer’s disease: A comprehensive review.Health Psychol. Res.10:31925. 10.52965/001c.31925
66
HasanS.KhatriN.RahmanZ.MenezesA.MartiniJ.ShehjarF.et al (2023). Neuroprotective potential of flavonoids in brain disorders.Brain Sci.13:1258. 10.3390/brainsci13091258
67
HirschS.ReicholdJ.SchneiderM.SzékelyG.WeberB. (2012). Topology and hemodynamics of the cortical cerebrovascular system.J. Cereb. Blood Flow Metab.32952–967. 10.1038/jcbfm.2012.39
68
InnesK.SelfeT.KhalsaD.KandatiS. (2017). Meditation and music improve memory and cognitive function in adults with subjective cognitive decline: A pilot randomized controlled trial.J. Alzheimers Dis.56899–916. 10.3233/JAD-160867
69
JainR.SharmaV. K. (2021). Development, characterization and evaluation of lactoferrin conjugated and memantine loaded Peg-Plga nanoparticles for the treatment of Alzheimer’s disease.J. Pharm Res. Int.33492–497. 10.9734/jpri/2021/v33i63a36091
70
JayatungaD.HoneE.BharadwajP.GargM.VerdileG.GuilleminG.et al (2020). Targeting mitophagy in Alzheimer’s disease.J. Alzheimers Dis.781273–1297. 10.3233/JAD-191258
71
JiangC.LiG.HuangP.LiuZ.ZhaoB. (2017). The gut microbiota and Alzheimer’s disease.J. Alzheimers Dis.58:1141. 10.3233/JAD-161141
72
JinY.SumsuzzmanD.ChoiJ.KangH.LeeS.HongY. (2018). Molecular and functional interaction of the myokine irisin with physical exercise and Alzheimer’s disease.Molecules23:3229. 10.3390/molecules23123229
73
KalariaR.HarikS. (1989). Reduced glucose transporter at the blood-brain barrier and in cerebral cortex in Alzheimer disease.J. Neurochem.531083–1088. 10.1111/j.1471-4159.1989.tb07399.x
74
KellarD.CraftS. (2020). Brain insulin resistance in Alzheimer’s disease and related disorders: Mechanisms and therapeutic approaches.Lancet Neurol.19758–766. 10.1016/S1474-4422(20)30231-3
75
KerwinD.AbdelnourC.CaramelliP.OgunniyiA.ShiJ.ZetterbergH.et al (2022). Alzheimer’s disease diagnosis and management: Perspectives from around the world.Alzheimers Dement.14:e12334. 10.1002/dad2.12334
76
KeshavanA.WellingtonH.ChenZ.KhatunA.ChapmanM.HartM.et al (2021). Concordance of CSF measures of Alzheimer’s pathology with amyloid PET status in a preclinical cohort: A comparison of Lumipulse and established immunoassays.Alzheimers Dement.13:e12131. 10.1002/dad2.12131
77
KhalsaD. (2015). Stress, meditation, and Alzheimer’s disease prevention: Where the evidence stands.J. Alzheimers Dis.481–12. 10.3233/JAD-142766
78
KhalsaD.AmenD.HanksC.MoneyN.NewbergA. (2009). Cerebral blood flow changes during chanting meditation.Nuclear Med. Commun.30956–961. 10.1097/MNM.0b013e32832fa26c
79
KhanH.UllahH.AschnerM.CheangW.AkkolE. (2020). Neuroprotective effects of quercetin in Alzheimer’s disease.Biomolecules10:59. 10.3390/biom10010059
80
Kiđemet-PiskačS.Babić LekoM.BlažekovićA.Langer HorvatL.KlepacN.SonickiZ.et al (2018). Evaluation of cerebrospinal fluid phosphorylated tau231 as a biomarker in the differential diagnosis of Alzheimer’s disease and vascular dementia.CNS Neurosci. Ther.24734–740. 10.1111/cns.12814
81
KimE.KimH.JedrychowskiM.BakiasiG.ParkJ.KruskopJ.et al (2023). Irisin reduces amyloid-β by inducing the release of neprilysin from astrocytes following downregulation of ERK-STAT3 signaling.Neuron111:3619–3633.e8. 10.1016/j.neuron.2023.08.012
82
KimuraT.IshiguroK.HisanagaS. (2014). Physiological and pathological phosphorylation of tau by Cdk5.Front. Mol. Neurosci.7:65. 10.3389/fnmol.2014.00065
83
KinneyJ.BemillerS.MurtishawA.LeisgangA.SalazarA.LambB. (2018). Inflammation as a central mechanism in Alzheimer’s disease.Alzheimers Dement.4575–590. 10.1016/j.trci.2018.06.014
84
KnopmanD.JonesD.GreiciusM. (2021). Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019.Alzheimers Dement.17696–701. 10.1002/alz.12213
85
KolbH.AndrésJ. (2017). Tau positron emission tomography imaging.Cold Spring Harb. Perspect. Biol.9:a023721. 10.1101/cshperspect.a023721
86
KurkinenM. (2023). Lecanemab (Leqembi) is not the right drug for patients with Alzheimer’s disease.Adv. Clin. Exp. Med.32943–947. 10.17219/acem/171379
87
LangeK. W.LangeK. M.Makulska-GertrudaE.NakamuraY.ReissmannA.KanayaS.et al (2017). Ketogenic diets and Alzheimer’s disease.Food Sci. Hum. Wellness6:3. 10.1016/j.fshw.2016.10.003
88
LeblhuberF.EhrlichD.SteinerK.GeislerS.FuchsD.LanserL.et al (2021). The immunopathogenesis of Alzheimer’s disease is related to the composition of gut microbiota.Nutrients13:361. 10.3390/nu13020361
89
LeeI.JungK.KimI.LeeH.KimM.YunS.et al (2015). Human neural stem cells alleviate Alzheimer-like pathology in a mouse model.Mol. Neurodegener.10:38. 10.1186/s13024-015-0035-6
90
LiZ.ZhaoT.ShiM.WeiY.HuangX.ShenJ.et al (2023). Polyphenols: Natural food grade biomolecules for treating neurodegenerative diseases from a multi-target perspective.Front. Nutr.10:1139558. 10.3389/fnut.2023.1139558
91
LiljaA.MalmstenL.RöjdnerJ.VoytenkoL.VerkhratskyA.ÖgrenS.et al (2015). Neural stem cell transplant-induced effect on neurogenesis and cognition in Alzheimer Tg2576 mice is inhibited by concomitant treatment with amyloid-lowering or cholinergic α7 nicotinic receptor drugs.Neural Plast.2015:370432. 10.1155/2015/370432
92
LiuY.LiuF.IqbalK.Grundke-IqbalI.GongC. (2008). Decreased glucose transporters correlate to abnormal hyperphosphorylation of tau in Alzheimer disease.FEBS Lett.582359–364. 10.1016/j.febslet.2007.12.035
93
López-OrtizS.Pinto-FragaJ.ValenzuelaP.Martín-HernándezJ.SeisdedosM.García-LópezO.et al (2021). Physical exercise and Alzheimer’s disease: Effects on pathophysiological molecular pathways of the disease.Int. J. Mol. Sci.22:2897. 10.3390/ijms22062897
94
LourencoM.de FreitasG.RaonyÍFerreiraS. T.De FeliceF. G. (2022). Irisin stimulates protective signaling pathways in rat hippocampal neurons.Front. Cell. Neurosci.16:953991. 10.3389/fncel.2022.953991
95
LourencoM.FerreiraS.FeliceF. D. (2017). FNDC5/irisin corrects memory deficits in animal models of Alzheimer’s disease.J. Neurochem.142:58.
96
LourencoM.FrozzaR.de FreitasG.ZhangH.KincheskiG.RibeiroF.et al (2019). Exercise-linked FNDC5/irisin rescues synaptic plasticity and memory defects in Alzheimer’s models.Nat. Med.25165–175. 10.1038/s41591-018-0275-4
97
LučiūnaitėA.McManusR.JankunecM.RáczI.DansokhoC.DalgėdienėI.et al (2020). Soluble Aβ oligomers and protofibrils induce NLRP3 inflammasome activation in microglia.J. Neurochem.155650–661. 10.1111/jnc.14945
98
Luna-MuñozJ.Chávez-MacíasL.García-SierraF.MenaR. (2007). Earliest stages of tau conformational changes are related to the appearance of a sequence of specific phospho-dependent tau epitopes in Alzheimer’s disease.J. Alzheimers Dis.12365–375. 10.3233/jad-2007-12410
99
MaH.JohnsonS.LiuW.DaSilvaN.MeschwitzS.DainJ.et al (2018). Evaluation of polyphenol anthocyanin-enriched extracts of blackberry, black raspberry, blueberry, cranberry, red raspberry, and strawberry for free radical scavenging, reactive carbonyl species trapping, anti-glycation, anti-β-amyloid aggregation, and microglial neuroprotective effects.Int. J. Mol. Sci.19:461. 10.3390/ijms19020461
100
MaccioniR.FaríasG.MoralesI.NavarreteL. (2010). The revitalized tau hypothesis on Alzheimer’s disease.Arch. Med. Res.41226–231. 10.1016/j.arcmed.2010.03.007
101
MaccioniR.LavadosM.GuillónM.MujicaC.BoschR.FaríasG.et al (2006). Anomalously phosphorylated tau and Abeta fragments in the CSF correlates with cognitive impairment in MCI subjects.Neurobiol. Aging27237–244. 10.1016/j.neurobiolaging.2005.01.011
102
MaccioniR.NavarreteL.GonzálezA.González-CanacerA.Guzmán-MartínezL.CortésN. (2020). Inflammation: A major target for compounds to control Alzheimer’s disease.J. Alzheimers Dis.761199–1213. 10.3233/JAD-191014
103
MaccioniR.RojoL.FernándezJ.KuljisR. (2009). The role of neuroimmunomodulation in Alzheimer’s disease.Ann. N. Y. Acad. Sci.1153240–246. 10.1111/j.1749-6632.2008.03972.x
104
MahalakshmiB.MauryaN.LeeS.Bharath KumarV. (2020). Possible neuroprotective mechanisms of physical exercise in neurodegeneration.Int. J. Mol. Sci.21:5895. 10.3390/ijms21165895
105
MaschioC.NiR. (2022). Amyloid and Tau positron emission tomography imaging in Alzheimer’s disease and other tauopathies.Front. Aging Neurosci.14:838034. 10.3389/fnagi.2022.838034
106
MattssonN.LönneborgA.BoccardiM.BlennowK.HanssonO. (2017). Clinical validity of cerebrospinal fluid Aβ42, tau, and phospho-tau as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework.Neurobiol. Aging52196–213. 10.1016/j.neurobiolaging.2016.02.034
107
McCaddonA.MillerJ. (2023). Homocysteine-a retrospective and prospective appraisal.Front. Nutr.10:1179807. 10.3389/fnut.2023.1179807
108
McGrowderD.MillerF.VazK.NwokochaC.Wilson-ClarkeC.Anderson-CrossM.et al (2021). Cerebrospinal fluid biomarkers of Alzheimer’s disease: Current evidence and future perspectives.Brain Sci.11:215. 10.3390/brainsci11020215
109
MehrdadJ.LeilaE.EmsehgolN. (2023). The effect of vitamin B12 on synaptic plasticity of hippocampus in Alzheimer’s disease model rats.Int. J. Neurosci.133654–659. 10.1080/00207454.2021.1962863
110
MengQ.LinM.TzengI. (2020). Relationship between exercise and Alzheimer’s disease: A narrative literature review.Front. Neurosci.14:131. 10.3389/fnins.2020.00131
111
MeyerM.KirmessK.EastwoodS.Wente-RothT.IrvinF.HolubaschM.et al (2024). Clinical validation of the PRECIVITYAD2 blood test: A mass spectrometry-based test with algorithm combining %p-tau217 and Aβ42/40 ratio to identify presence of brain amyloid.Alzheimers Dement.203179–3192. 10.1002/alz.13764
112
MillerJ. (1999). Homocysteine and Alzheimer’s disease.Nutr. Rev.57126–129. 10.1111/j.1753-4887.1999.tb06936.x
113
MoralesI.JiménezJ.MancillaM.MaccioniR. (2013). Tau oligomers and fibrils induce activation of microglial cells.J. Alzheimers Dis.37849–856. 10.3233/JAD-131843
114
MorrisJ.VidoniE. D.JohnsonD.Van SciverA.MahnkenJ.HoneaR.et al (2017). Aerobic exercise for Alzheimer’s disease: A randomized controlled pilot trial.PLoS One12:e0170547. 10.1371/journal.pone.0170547
115
MroczkoB.GroblewskaM.Litman-ZawadzkaA. (2019). The role of protein misfolding and tau oligomers (TauOs) in Alzheimer’s disease (AD).Int. J. Mol. Sci.20:4661. 10.3390/ijms20194661
116
MukadamA.MillerL.SmithA.VaysburdM.SakyaS.SanfordS.et al (2023). Cytosolic antibody receptor TRIM21 is required for effective tau immunotherapy in mouse models.Science3791336–1341. 10.1126/science.abn1366
117
MushtaqG.KhanJ.KumosaniT.KamalM. (2015). Alzheimer’s disease and type 2 diabetes via chronic inflammatory mechanisms.Saudi J. Biol. Sci.224–13. 10.1016/j.sjbs.2014.05.003
118
NortleyR.KorteN.IzquierdoP.HirunpattarasilpC.MishraA.JaunmuktaneZ.et al (2019). Amyloid β oligomers constrict human capillaries in Alzheimer’s disease via signaling to pericytes.Science365:eaav9518. 10.1126/science.aav9518
119
NovakP.ZilkaN.ZilkovaM.KovacechB.SkrabanaR.OndrusM.et al (2019). AADvac1, an active immunotherapy for Alzheimer’s disease and non alzheimer tauopathies: An overview of preclinical and clinical development.J. Prev. Alzheimers Dis.663–69. 10.14283/jpad.2018.45
120
OliveiraT.MoraisA.Dos ReisP.PalotásA.VieiraL. B. (2024). A potential role for the ketogenic diet in Alzheimer’s disease treatment: Exploring pre-clinical and clinical evidence.Metabolites14:25. 10.3390/metabo14010025
121
OzdemirL.AkdemirN. (2009). Effects of multisensory stimulation on cognition, depression and anxiety levels of mildly-affected Alzheimer’s patients.J. Neurol. Sci.283211–213. 10.1016/j.jns.2009.02.367
122
ParsonsC.DanyszW.DekundyA.PulteI. (2013). Memantine and cholinesterase inhibitors: Complementary mechanisms in the treatment of Alzheimer’s disease.Neurotox. Res.24358–369. 10.1007/s12640-013-9398-z
123
PR Newswire (2023). FDA grants traditional approval for LEQEMBI® (lecanemab-irmb) for the treatment of Alzheimer’s disease.Chicago, IL: PR Newswire US.
124
RashB.RamdasK.AgafonovaN.NaiotiE.McClain-MossL.ZainulZ.et al (2025). Allogeneic mesenchymal stem cell therapy with laromestrocel in mild Alzheimer’s disease: A randomized controlled phase 2a trial.Nat. Med.311257–1266. 10.1038/s41591-025-03559-0
125
ReddyV.AryalP.RobinsonS.RafiuR.ObrenovichM.PerryG. (2020). Polyphenols in Alzheimer’s disease and in the gut-brain axis.Microorganisms8:199. 10.3390/microorganisms8020199
126
ReissA.GulkarovS.JacobB.SrivastavaA.PinkhasovA.GomolinI.et al (2024). Mitochondria in Alzheimer’s disease pathogenesis.Life14:196. 10.3390/life14020196
127
RodaA.Serra-MirG.Montoliu-GayaL.TiesslerL.VillegasS. (2022). Amyloid-beta peptide and tau protein crosstalk in Alzheimer’s disease.Neural Regen. Res.171666–1674. 10.4103/1673-5374.332127
128
RodrigueK.KennedyK.DevousM.RieckJ.HebrankA.Diaz-ArrastiaR.et al (2012). β-Amyloid burden in healthy aging: Regional distribution and cognitive consequences.Neurology78387–395. 10.1212/WNL.0b013e318245d295
129
Rubio-PerezJ.Morillas-RuizJ. M. (2012). A review: Inflammatory process in Alzheimer’s disease, role of cytokines.ScientificWorldJournal2012:756357. 10.1100/2012/756357
130
Sadigh-EteghadS.SabermaroufB.MajdiA.TalebiM.FarhoudiM.MahmoudiJ. (2015). Amyloid-beta: A crucial factor in Alzheimer’s disease.Med. Principles Pract.241–10. 10.1159/000369101
131
SaitoT.ObaT.ShimizuS.AsadaA.IijimaK.AndoK. (2019). Cdk5 increases MARK4 activity and augments pathological tau accumulation and toxicity through tau phosphorylation at Ser262.Hum. Mol. Genet.283062–3071. 10.1093/hmg/ddz120
132
SchultzS.LarsonJ.OhJ.KoscikR.DowlingM.GallagherC.et al (2015). Participation in cognitively-stimulating activities is associated with brain structure and cognitive function in preclinical Alzheimer’s disease.Brain Imaging Behav.9729–736. 10.1007/s11682-014-9329-5
133
SebastiãoI.CandeiasE.SantosM.de OliveiraC.MoreiraP.DuarteA. (2014). Insulin as a bridge between type 2 diabetes and alzheimer disease - How anti-diabetics could be a solution for dementia.Front. Endocrinol.5:110. 10.3389/fendo.2014.00110
134
SeshadriS.BeiserA.SelhubJ.JacquesP.RosenbergI.D’AgostinoR.et al (2002). Plasma homocysteine as a risk factor for dementia and Alzheimer’s disease.N. Engl. J. Med.346476–483. 10.1056/NEJMoa011613
135
ShaoS.YeX.SuW.WangY. (2023). Curcumin alleviates Alzheimer’s disease by inhibiting inflammatory response, oxidative stress and activating the AMPK pathway.J. Chem. Neuroanat.134:102363. 10.1016/j.jchemneu.2023.102363
136
ShiY.LinF.LiY.WangY.ChenX.MengF.et al (2023). Association of pro-inflammatory diet with increased risk of all-cause dementia and Alzheimer’s dementia: A prospective study of 166,377 UK Biobank participants.BMC Med.21:266. 10.1186/s12916-023-02940-5
137
ShobeiriP.KarimiA.MomtazmaneshS.TeixeiraA.TeunissenC.van WegenE.et al (2022). Exercise-induced increase in blood-based brain-derived neurotrophic factor (BDNF) in people with multiple sclerosis: A systematic review and meta-analysis of exercise intervention trials.PLoS One17:e0264557. 10.1371/journal.pone.0264557
138
SinghD. (2022). Astrocytic and microglial cells as the modulators of neuroinflammation in Alzheimer’s disease.J. Neuroinflamm.19:206. 10.1186/s12974-022-02565-0
139
SlachevskyA.Guzmán-MartínezL.DelgadoC.ReyesP.FaríasG. A.Muñoz-NeiraC.et al (2016). Tau platelets correlate with regional brain atrophy in patients with Alzheimer’s disease.J. Alzheimers Dis.551595–1603. 10.3233/JAD-160652
140
SöderbergL.JohannessonM.NygrenP.LaudonH.ErikssonF.OsswaldG.et al (2023). Lecanemab, aducanumab, and gantenerumab - binding profiles to different forms of amyloid-beta might explain efficacy and side effects in clinical trials for Alzheimer’s disease.Neurotherapeutics20195–206. 10.1007/s13311-022-01308-6
141
SohanakiH.BaluchnejadmojaradT.NikbakhtF.RoghaniM. (2016). Pelargonidin improves memory deficit in amyloid β25-35 rat model of Alzheimer’s disease by inhibition of glial activation, cholinesterase, and oxidative stress.Biomed. Pharmacother.8385–91. 10.1016/j.biopha.2016.06.021
142
SolchR.AigbogunJ.VoyiadjisA.TalkingtonG.DarensbourgR.O’ConnellS.et al (2022). Mediterranean diet adherence, gut microbiota, and Alzheimer’s or Parkinson’s disease risk: A systematic review.J. Neurol. Sci.434:120166. 10.1016/j.jns.2022.120166
143
StelzmannR.SchnitzleinH.MurtaghF. (1995). An English translation of Alzheimer’s 1907 paper, “Uber eine eigenartige Erkankung der Hirnrinde”.Clin. Anat.8429–431. 10.1002/ca.980080612
144
StuartK.PadgettC. (2020). A systematic review of the association between psychological stress and dementia risk in humans.J. Alzheimers Dis.78335–352. 10.3233/JAD-191096
145
SubashS.EssaM.Al-AdawiS.MemonM.ManivasagamT.AkbarM. (2014). Neuroprotective effects of berry fruits on neurodegenerative diseases.Neural Regen. Res.91557–1566. 10.4103/1673-5374.139483
146
TangB.WangY.RenJ. (2023). Basic information about memantine and its treatment of Alzheimer’s disease and other clinical applications.Ibrain9340–348. 10.1002/ibra.12098
147
TangM.TaghibiglouC.LiuJ. (2017). The mechanisms of action of curcumin in Alzheimer’s disease.J. Alzheimers Dis.58:188. 10.3233/JAD-170188
148
ThatteU. (2001). AN-1792 (Elan).Curr. Opin. Invest. Drugs2663–667.
149
ToledoJ.ArnoldS.RaibleK.BrettschneiderJ.XieS.GrossmanM.et al (2013). Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer’s coordinating centre.Brain1362697–2706. 10.1093/brain/awt188
150
Trejo-LopezJ.YachnisA.ProkopS. (2022). Neuropathology of Alzheimer’s disease.Neurotherapeutics19173–185. 10.1007/s13311-021-01146-y
151
TwarowskiB.HerbetM. (2023). Inflammatory processes in Alzheimer’s disease-pathomechanism, diagnosis and treatment: A review.Int. J. Mol. Sci.24:6518. 10.3390/ijms24076518
152
Vallejo-JohnsonM. A.Marcial-VelasteguiP. (2018). Influencia del estrés en la enfermedad de Alzheimer. // Stress influence in Alzheimer’s disease.Ciencia UNEMI10123–133. 10.29076/issn.2528-7737vol10iss25.2017pp123-133p
153
VaresiA.PierellaE.RomeoM.PicciniG.AlfanoC.BjørklundG.et al (2022). The potential role of gut microbiota in Alzheimer’s disease: From diagnosis to treatment.Nutrients14:668. 10.3390/nu14030668
154
VoulgaropoulouS.van AmelsvoortT.PrickaertsJ.VingerhoetsC. (2019). The effect of curcumin on cognition in Alzheimer’s disease and healthy aging: A systematic review of pre-clinical and clinical studies.Brain Res.1725:146476. 10.1016/j.brainres.2019.146476
155
WangC.WangP.ChiuM.FinstadC.LinF.LynnS.et al (2017). UB-311, a novel UBITh® amyloid β peptide vaccine for mild Alzheimer’s disease.Alzheimers Dement.3262–272. 10.1016/j.trci.2017.03.005
156
WangC.ZongS.CuiX.WangX.WuS.WangL.et al (2023). The effects of microglia-associated neuroinflammation on Alzheimer’s disease.Front. Immunol.14:1117172. 10.3389/fimmu.2023.1117172
157
WangY.Rosa-NetoP.GauthierS. (2023). Advanced brain imaging for the diagnosis of Alzheimer disease.Curr. Opin. Neurol.36481–490. 10.1097/WCO.0000000000001198
158
WangR.HeQ.HanC.WangH.ShiL.CheY. (2023). A deep learning framework for identifying Alzheimer’s disease using fMRI-based brain network.Front. Neurosci.17:1177424. 10.3389/fnins.2023.1177424
159
WeningerS.CarrilloM.DunnB.AisenP.BatemanR.KotzJ.et al (2016). Collaboration for Alzheimer’s prevention: Principles to guide data and sample sharing in preclinical Alzheimer’s disease trials.Alzheimers Dement.12631–632. 10.1016/j.jalz.2016.04.001
160
WestT.HuY.VergheseP.BatemanR.BraunsteinJ.FogelmanI.et al (2017). Preclinical and clinical development of ABBV-8E12, a humanized anti-tau antibody, for treatment of Alzheimer’s disease and other tauopathies.J. Prev. Alzheimers Dis.4236–241. 10.14283/jpad.2017.36
161
XiaC. F.ArteagaJ.ChenG.GangadharmathU.GomezL. F.KasiD.et al (2013). [18F]T807, a novel tau positron emission tomography imaging agent for Alzheimer’s disease.Alzheimers Dement.9:8. 10.1016/j.jalz.2012.11.008
162
XuY.JiangC.WuJ.LiuP.DengX.ZhangY.et al (2022). Ketogenic diet ameliorates cognitive impairment and neuroinflammation in a mouse model of Alzheimer’s disease.CNS Neurosci. Ther.28580–592. 10.1111/cns.13779
163
Zamarrón CassinelloM.Tárraga MestreL.Fernández-BallesterosR. (2008). [Cognitive plasticity in Alzheimer’s disease patients receiving cognitive stimulation programs].Psicothema20432–437.
164
ZaplaticE.BuleM.ShahS.UddinM.NiazK. (2019). Molecular mechanisms underlying protective role of quercetin in attenuating Alzheimer’s disease.Life Sci.224109–119. 10.1016/j.lfs.2019.03.055
165
ZhangQ.WuH.WangY.GuG.ZhangW.XiaR. (2016). Neural stem cell transplantation decreases neuroinflammation in a transgenic mouse model of Alzheimer’s disease.J. Neurochem.136815–825. 10.1111/jnc.13413
166
ZhangX.ChenJ.OuyangD.LuJ. (2020). Quercetin in Animal models of Alzheimer’s disease: A systematic review of preclinical studies.Int. J. Mol. Sci.21:493. 10.3390/ijms21020493
167
ZhaoZ.NelsonA.BetsholtzC.ZlokovicB. (2015). Establishment and dysfunction of the blood-brain barrier.Cell1631064–1078. 10.1016/j.cell.2015.10.067
168
ZhengC.ZhouX.WangJ. (2016). The dual roles of cytokines in Alzheimer’s disease: Update on interleukins, TNF-α, TGF-β and IFN-γ.Transl. Neurodegener.5:7. 10.1186/s40035-016-0054-4
169
ZhengY.KesavapanyS.GravellM.HamiltonR.SchubertM.AminN.et al (2005). A Cdk5 inhibitory peptide reduces tau hyperphosphorylation and apoptosis in neurons.EMBO J.24209–220. 10.1038/sj.emboj.7600441
Summary
Keywords
Alzheimer’s disease, etiopathology, immunomodulation, prevention, early detection diagnosis, nutraceuticals
Citation
González A, Geywitz S and Maccioni RB (2025) Alzheimer’s disease: where do we stand now and what are the strategic interventions?. Front. Cell. Neurosci. 19:1655342. doi: 10.3389/fncel.2025.1655342
Received
27 June 2025
Accepted
21 August 2025
Published
10 September 2025
Volume
19 - 2025
Edited by
Mark A. DeCoster, Louisiana Tech University, United States
Updates
Copyright
© 2025 González, Geywitz and Maccioni.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Ricardo B. Maccioni, rmaccioni45@gmail.com
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.